167 related articles for article (PubMed ID: 37853454)
1. INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas.
Grassl N; Sahm K; Süße H; Poschke I; Bunse L; Bunse T; Boschert T; Mildenberger I; Rupp AK; Ewinger MP; Lanz LM; Denk M; Tabatabai G; Ronellenfitsch MW; Herrlinger U; Glas M; Krex D; Vajkoczy P; Wick A; Harting I; Sahm F; von Deimling A; Bendszus M; Wick W; Platten M
Neurol Res Pract; 2023 Oct; 5(1):55. PubMed ID: 37853454
[TBL] [Abstract][Full Text] [Related]
2. AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas.
Bunse L; Rupp AK; Poschke I; Bunse T; Lindner K; Wick A; Blobner J; Misch M; Tabatabai G; Glas M; Schnell O; Gempt J; Denk M; Reifenberger G; Bendszus M; Wuchter P; Steinbach JP; Wick W; Platten M
Neurol Res Pract; 2022 May; 4(1):20. PubMed ID: 35599302
[TBL] [Abstract][Full Text] [Related]
3. A H3K27M-targeted vaccine in adults with diffuse midline glioma.
Grassl N; Poschke I; Lindner K; Bunse L; Mildenberger I; Boschert T; Jähne K; Green EW; Hülsmeyer I; Jünger S; Kessler T; Suwala AK; Eisele P; Breckwoldt MO; Vajkoczy P; Grauer OM; Herrlinger U; Tonn JC; Denk M; Sahm F; Bendszus M; von Deimling A; Winkler F; Wick W; Platten M; Sahm K
Nat Med; 2023 Oct; 29(10):2586-2592. PubMed ID: 37735561
[TBL] [Abstract][Full Text] [Related]
4. K27M-mutant histone-3 as a novel target for glioma immunotherapy.
Ochs K; Ott M; Bunse T; Sahm F; Bunse L; Deumelandt K; Sonner JK; Keil M; von Deimling A; Wick W; Platten M
Oncoimmunology; 2017; 6(7):e1328340. PubMed ID: 28811969
[TBL] [Abstract][Full Text] [Related]
5. Purine salvage promotes treatment resistance in H3K27M-mutant diffuse midline glioma.
Peterson ER; Sajjakulnukit P; Scott AJ; Heaslip C; Andren A; Wilder-Romans K; Zhou W; Palavalasa S; Korimerla N; Lin A; O'Brien A; Kothari A; Zhao Z; Zhang L; Morgan MA; Venneti S; Koschmann C; Jabado N; Lyssiotis CA; Castro MG; Wahl DR
Cancer Metab; 2024 Apr; 12(1):11. PubMed ID: 38594734
[TBL] [Abstract][Full Text] [Related]
6. Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes.
Huang T; Garcia R; Qi J; Lulla R; Horbinski C; Behdad A; Wadhwani N; Shilatifard A; James C; Saratsis AM
Oncotarget; 2018 Dec; 9(98):37112-37124. PubMed ID: 30647848
[TBL] [Abstract][Full Text] [Related]
7. Adaptive rewiring of purine metabolism promotes treatment resistance in H3K27M-mutant diffuse midline glioma.
Peterson ER; Sajjakulnukit P; Scott AJ; Heaslip C; Andren A; Wilder-Romans K; Zhou W; Palavalasa S; Korimerla N; Lin A; Obrien A; Kothari A; Zhao Z; Zhang L; Morgan MA; Venneti S; Koschmann C; Jabado N; Lyssiotis CA; Castro MG; Wahl DR
Res Sq; 2023 Sep; ():. PubMed ID: 37790517
[TBL] [Abstract][Full Text] [Related]
8. A novel mouse model of diffuse midline glioma initiated in neonatal oligodendrocyte progenitor cells highlights cell-of-origin dependent effects of H3K27M.
Tomita Y; Shimazu Y; Somasundaram A; Tanaka Y; Takata N; Ishi Y; Gadd S; Hashizume R; Angione A; Pinero G; Hambardzumyan D; Brat DJ; Hoeman CM; Becher OJ
Glia; 2022 Sep; 70(9):1681-1698. PubMed ID: 35524725
[TBL] [Abstract][Full Text] [Related]
9. Pediatric Diffuse Midline Gliomas H3 K27M-Mutant and Non-Histone Mutant Midline High-Grade Gliomas in Neurofibromatosis Type 1 in Comparison With Non-Syndromic Children: A Single-Center Pilot Study.
Garibotto F; Madia F; Milanaccio C; Verrico A; Piccardo A; Tortora D; Piatelli G; Diana MC; Capra V; Garrè ML; Rossi A; Morana G
Front Oncol; 2020; 10():795. PubMed ID: 32582540
[No Abstract] [Full Text] [Related]
10. Identification of a differentiation stall in epithelial mesenchymal transition in histone H3-mutant diffuse midline glioma.
Sanders LM; Cheney A; Seninge L; van den Bout A; Chen M; Beale HC; Kephart ET; Pfeil J; Learned K; Lyle AG; Bjork I; Haussler D; Salama SR; Vaske OM
Gigascience; 2020 Dec; 9(12):. PubMed ID: 33319914
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age.
Vuong HG; Ngo TNM; Le HT; Dunn IF
J Neurooncol; 2022 Jul; 158(3):405-412. PubMed ID: 35606633
[TBL] [Abstract][Full Text] [Related]
12. Diffuse midline glioma H3K27M mutation in adult: A case report.
Bhattarai AM; Mainali G; Jha P; Karki P; Adhikari A; Pandit A; Bhattarai AM
Ann Med Surg (Lond); 2022 Apr; 76():103567. PubMed ID: 35495373
[TBL] [Abstract][Full Text] [Related]
13. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.
Mueller S; Taitt JM; Villanueva-Meyer JE; Bonner ER; Nejo T; Lulla RR; Goldman S; Banerjee A; Chi SN; Whipple NS; Crawford JR; Gauvain K; Nazemi KJ; Watchmaker PB; Almeida ND; Okada K; Salazar AM; Gilbert RD; Nazarian J; Molinaro AM; Butterfield LH; Prados MD; Okada H
J Clin Invest; 2020 Dec; 130(12):6325-6337. PubMed ID: 32817593
[TBL] [Abstract][Full Text] [Related]
14. Endogenous H3.3K27M derived peptide restricted to HLA-A∗02:01 is insufficient for immune-targeting in diffuse midline glioma.
Wang SS; Pandey K; Watson KA; Abbott RC; Mifsud NA; Gracey FM; Ramarathinam SH; Cross RS; Purcell AW; Jenkins MR
Mol Ther Oncolytics; 2023 Sep; 30():167-180. PubMed ID: 37674626
[TBL] [Abstract][Full Text] [Related]
15. STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma.
Zhang L; Nesvick CL; Day CA; Choi J; Lu VM; Peterson T; Power EA; Anderson JB; Hamdan FH; Decker PA; Simons R; Welby JP; Siada R; Ge J; Kaptzan T; Johnsen SA; Hinchcliffe EH; Daniels DJ
Neuro Oncol; 2022 Oct; 24(10):1700-1711. PubMed ID: 35397475
[TBL] [Abstract][Full Text] [Related]
16. Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas.
Bechet D; Gielen GG; Korshunov A; Pfister SM; Rousso C; Faury D; Fiset PO; Benlimane N; Lewis PW; Lu C; David Allis C; Kieran MW; Ligon KL; Pietsch T; Ellezam B; Albrecht S; Jabado N
Acta Neuropathol; 2014 Nov; 128(5):733-41. PubMed ID: 25200321
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy with anlotinib for a H3K27M mutation diffuse midline glioma patient with PDGFR-α mutation: a case report.
Wang Q; Niu W; Pan H
Acta Neurochir (Wien); 2022 Aug; 164(8):2063-2066. PubMed ID: 34812950
[TBL] [Abstract][Full Text] [Related]
18. Histone H3 K27M-mediated regulation of cancer cell stemness and differentiation in diffuse midline glioma.
Sharma M; Barravecchia I; Magnuson B; Ferris SF; Apfelbaum A; Mbah NE; Cruz J; Krishnamoorthy V; Teis R; Kauss M; Koschmann C; Lyssiotis CA; Ljungman M; Galban S
Neoplasia; 2023 Oct; 44():100931. PubMed ID: 37647805
[TBL] [Abstract][Full Text] [Related]
19. Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity.
López-Pérez CA; Franco-Mojica X; Villanueva-Gaona R; Díaz-Alba A; Rodríguez-Florido MA; Navarro VG
J Neurooncol; 2022 Jul; 158(3):369-378. PubMed ID: 35567713
[TBL] [Abstract][Full Text] [Related]
20. H3.3K27M Mutation Controls Cell Growth and Resistance to Therapies in Pediatric Glioma Cell Lines.
Rakotomalala A; Bailleul Q; Savary C; Arcicasa M; Hamadou M; Huchedé P; Hochart A; Restouin A; Castellano R; Collette Y; Dieny E; Vincent A; Angrand PO; Le Bourhis X; Leblond P; Furlan A; Castets M; Pasquier E; Meignan S
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
